Human Lactoferrin and Peptides Derived from Its N Terminus Are Highly Effective against Infections with Antibiotic-Resistant Bacteria

ABSTRACT Since human lactoferrin (hLF) binds to bacterial products through its highly positively charged N terminus, we investigated which of the two cationic domains is involved in its bactericidal activity. The results revealed that hLF lacking the first three residues (hLF−3N) was less efficient than hLF in killing of antibiotic-resistant Staphylococcus aureus, Listeria monocytogenes, and Klebsiella pneumoniae. Both hLF preparations failed to kill Escherichia coli O54. In addition, hLF−3N was less effective than hLF in reducing the number of viable bacteria in mice infected with antibiotic-resistant S. aureus and K. pneumoniae. Studies with synthetic peptides corresponding to the first 11 N-terminal amino acids, designated hLF(1–11), and fragments thereof demonstrated that peptides lacking the first three N-terminal residues are less effective than hLF(1–11) in killing of bacteria. Furthermore, a peptide corresponding to residues 21 to 31, which comprises the second cationic domain, was less effective than hLF(1–11) in killing of bacteria in vitro and in mice having an infection with antibiotic-resistant S. aureus or K. pneumoniae. Using fluorescent probes, we found that bactericidal hLF peptides, but not nonbactericidal peptides, caused an increase of the membrane permeability. In addition, hLF killed the various bacteria, most probably by inducing intracellular changes in these bacteria without affecting the membrane permeability. Together, hLF and peptides derived from its N terminus are highly effective against infections with antibiotic-resistant S. aureus and K. pneumoniae, and the first two arginines play an essential role in this activity.

[1]  I. Mattsby‐Baltzer,et al.  Human Lactoferrin and Peptides Derived from a Surface-Exposed Helical Region Reduce Experimental Escherichia coli Urinary Tract Infection in Mice , 2000, Infection and Immunity.

[2]  E. Pauwels,et al.  Technetium-99m labelled antimicrobial peptides discriminate between bacterial infections and sterile inflammations , 2000, European Journal of Nuclear Medicine.

[3]  Y. Shai,et al.  Mechanism of the binding, insertion and destabilization of phospholipid bilayer membranes by alpha-helical antimicrobial and cell non-selective membrane-lytic peptides. , 1999, Biochimica et biophysica acta.

[4]  M. Willcox,et al.  Elucidation of the antistaphylococcal action of lactoferrin and lysozyme. , 1999, Journal of medical microbiology.

[5]  T. Abee,et al.  The Cellular Target of Histatin 5 on Candida albicans Is the Energized Mitochondrion* , 1999, The Journal of Biological Chemistry.

[6]  D. Mann,et al.  Neutralization of Endotoxin In Vitro and In Vivo by a Human Lactoferrin-Derived Peptide , 1999, Infection and Immunity.

[7]  E. Pauwels,et al.  Antibacterial activity of human neutrophil defensins in experimental infections in mice is accompanied by increased leukocyte accumulation. , 1998, The Journal of clinical investigation.

[8]  A. Akimzhanov,et al.  Interaction of human milk lactoferrin with ATP. , 1998, Biochemistry. Biokhimiia.

[9]  H. Hayasawa,et al.  Bovine lactoferrin stimulates the phagocytic activity of human neutrophils: identification of its active domain. , 1998, Cellular immunology.

[10]  Vanya Gant,et al.  Structure-Function Relationship of Antibacterial Synthetic Peptides Homologous to a Helical Surface Region on Human Lactoferrin against Escherichia coli Serotype O111 , 1998, Infection and Immunity.

[11]  R. Bonnah,et al.  Bacterial lactoferrin receptors. , 1998, Advances in experimental medicine and biology.

[12]  P. V. van Berkel,et al.  N-terminal stretch Arg2, Arg3, Arg4 and Arg5 of human lactoferrin is essential for binding to heparin, bacterial lipopolysaccharide, human lysozyme and DNA. , 1997, The Biochemical journal.

[13]  V. Salmon,et al.  The N-terminal Arg2, Arg3 and Arg4 of human lactoferrin interact with sulphated molecules but not with the receptor present on Jurkat human lymphoblastic T-cells. , 1997, The Biochemical journal.

[14]  D. Dionysius,et al.  Antibacterial peptides of bovine lactoferrin: purification and characterization. , 1997, Journal of dairy science.

[15]  D. J. Mason,et al.  Antimicrobial action of rabbit leukocyte CAP18(106-137) , 1997, Antimicrobial agents and chemotherapy.

[16]  K. Hoek,et al.  Antibacterial activity in bovine lactoferrin-derived peptides , 1997, Antimicrobial agents and chemotherapy.

[17]  W. Shafer,et al.  Susceptibility of Neisseria gonorrhoeae to protegrins , 1996, Infection and immunity.

[18]  R. W. Evans,et al.  Antibacterial activity of peptides homologous to a loop region in human lactoferrin , 1996, FEBS letters.

[19]  V. Salmon,et al.  Lactoferrin-lipopolysaccharide interaction: involvement of the 28-34 loop region of human lactoferrin in the high-affinity binding to Escherichia coli 055B5 lipopolysaccharide. , 1995, The Biochemical journal.

[20]  G. A. Schellekens,et al.  The use of dedicated peptide libraries permits the discovery of high affinity binding peptides. , 1995, Journal of immunological methods.

[21]  T. Tsuji,et al.  A new fluorescence staining assay for visualizing living microorganisms in soil , 1995, Applied and environmental microbiology.

[22]  T. Ganz,et al.  Defensins and other endogenous peptide antibiotics of vertebrates , 1995, Journal of leukocyte biology.

[23]  O. Conneely,et al.  A System for Production of Commercial Quantities of Human Lactoferrin: A Broad Spectrum Natural Antibiotic , 1995, Bio/Technology.

[24]  D. Monroe,et al.  Characterization of the glycosaminoglycan-binding region of lactoferrin. , 1995, Archives of biochemistry and biophysics.

[25]  R. Houghten,et al.  The Role of Amphipathicity in the Folding, Self-association and Biological Activity of Multiple Subunit Small Proteins (*) , 1995, The Journal of Biological Chemistry.

[26]  D. Mann,et al.  Delineation of the glycosaminoglycan-binding site in the human inflammatory response protein lactoferrin. , 1994, The Journal of biological chemistry.

[27]  A. Forsgren,et al.  Lactoferrin binds to porins OmpF and OmpC in Escherichia coli , 1994, Infection and immunity.

[28]  R. Ellison The effects of lactoferrin on gram-negative bacteria. , 1994, Advances in experimental medicine and biology.

[29]  D. Atsma,et al.  The labeling of proteins and LDL with 99mTc: a new direct method employing KBH4 and stannous chloride. , 1993, Nuclear medicine and biology.

[30]  R. Lehrer,et al.  Protegrins: leukocyte antimicrobial peptides that combine features of corticostatic defensins and tachyplesins , 1993, FEBS letters.

[31]  K. Yamauchi,et al.  Antibacterial activity of lactoferrin and a pepsin-derived lactoferrin peptide fragment , 1993, Infection and immunity.

[32]  K. Yamauchi,et al.  Identification of the bactericidal domain of lactoferrin. , 1992, Biochimica et biophysica acta.

[33]  Miguel Calvo Rebollar,et al.  Biological role of lactoferrin. , 1992, Archives of disease in childhood.

[34]  K. Yamauchi,et al.  Potent antibacterial peptides generated by pepsin digestion of bovine lactoferrin. , 1991, Journal of dairy science.

[35]  T. Yip,et al.  Structurally intact (78-kDa) forms of maternal lactoferrin purified from urine of preterm infants fed human milk: identification of a trypsin-like proteolytic cleavage event in vivo that does not result in fragment dissociation. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[36]  R. Ellison,et al.  Damage of the outer membrane of enteric gram-negative bacteria by lactoferrin and transferrin , 1988, Infection and immunity.

[37]  J. Bullen The significance of iron in infection. , 1981, Reviews of infectious diseases.